Pfizer is testing an extra dose of its COVID-19 vaccine for babies and preschoolers enrolled in a study of the shots. Pfizer had been testing two very low-dose shots in
By LAURAN NEERGAARD AP Medical Writer Pfizer is testing an extra dose of its COVID-19 vaccine for babies and preschoolers after preliminary research hinted the usual two doses wouldn’t be enough. Pfizer had been testing very low-dose shots in children under age 5, with some data expected by year’s e…
Pfizer and BioNTech said Friday they expect to submit an application for the use of their COVID-19 vaccine in children under five years old in the "first half of 2022" as they test a third dose for the age group.&nb
Children ages 2-5 did not mount an adequate immune response to COVID-19 after being fully vaccinated with the Pfizer-BioNTech vaccine in a trial, the company said Friday, a setback to its efforts to get the shots cleared by regulators.
Pfizer is testing an extra dose of its COVID-19 vaccine for babies and preschoolers after preliminary research hinted the usual two doses wouldn't be enough.
Pfizer announced Friday that it wants to test a third dose of the Covid-19 vaccine in the under-fives, as the low dosage such small children can handle may not offer the same protection that older ch…
Pfizer said its special low-dose COVID-19 vaccine didn’t have as strong an immune response as expected in 2- to 4-year-olds, and it’s now testing three doses.
Children under 5 will have to wait a little longer for vaccine authorization as the omicron variant tests the resolve of coronavirus mitigation strategies across the globe.
Pfizer and BioNTech, which produced the first COVID-19 vaccine authorized in the U.S., say they will expand ongoing trials to include a third dose for children as young as 6 months old.
Pfizer and BioNTech announced on Thursday evening that they had submitted an application to the Food and Drug Administration (FDA) seeking full approval for the administration of their two-dose COVID-19 vaccine in children aged between 12 and 15.
Pfizer said Friday an early analysis showed a two-dose regime of its COVID vaccine wasn’t effective for some young kids, and it will amend an ongoing study to test a third dose. “Compared to the 16- to 25-year-old population in which high efficacy was demonstrated, non-inferiority was met for the 6-…
Vaccine maker Pfizer said Friday that trials of its vaccine in children ages 2 to 5 show it did not provide the expected immunity in kids this age and it is adding a third dose to the regimen.
Along with its partner BioNTech, the companies said they plan to apply for emergency authorization in the first half of 2022 if the study is successful.
By Maggie Fox and Virginia Langmaid, CNN Vaccine maker Pfizer said Friday that trials of its vaccine in children ages 2 to 5 show that it did not provide the expected immunity in kids this age, and it is adding a third dose to the regimen. The company decided to add the third dose for
